Otsuka Holdings CO ADR (OP:OTSKY)

37.73 -1.15 (-2.94%)

Delayed Quote Updated: 3:51 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Otsuka Holdings CO ADR

Why Axsome Therapeutics Stock Jumped Over 20% in April ↗

May 02, 2026

Axsome shares reached an all-time high last month, and there might be more to come.

Via The Motley Fool

Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market ↗

October 16, 2025

Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment.

Via Benzinga

TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines

February 06, 2025

From TANAKA PRECIOUS METAL GROUP Co., Ltd.

Via JCN Newswire

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results ↗

December 31, 2024

Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025.

Via Benzinga

OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q2 2024 ↗

August 23, 2024

Otsuka Holdings just reported results for the second quarter of 2024.

Via InvestorPlace

OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q1 2024 ↗

May 17, 2024

Otsuka Holdings just reported results for the first quarter of 2024.

Via InvestorPlace

Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study ↗

August 05, 2022

Via Benzinga

TANAKA to Provide Medals Representing the Event Concept with a Design of Gently Curved Circular Expansion for the Tokyo Legacy Half Marathon 2024

October 17, 2024

From Tanaka Holdings Co., Ltd.

Via JCN Newswire

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation ↗

April 16, 2024

IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.

Via Benzinga

Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo ↗

March 20, 2024

IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed.

Via Benzinga

Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension ↗

August 24, 2023

Medtronic Plc (NYSE: MDT) says the FDA Circulatory System Devices Panel (CSDP) voted unanimously (13-0) on safety and in favor (7-6) of the effectiveness of the Symplicity blood pressure procedure,

Via Benzinga

Why Are Akebia Therapeutics Shares Falling Today? ↗

May 16, 2022

Via Benzinga

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia ↗

March 30, 2022

Via Benzinga

Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device ↗

August 23, 2023

The FDA's Circulatory Systems Devices Panel of the Medical Devices Advisory Committee backed Recor Medical Inc and its parent company, Otsuka Medical Devices Co Ltd's

Via Benzinga

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation ↗

May 11, 2023

Otsuka Pharmaceutical Co Ltd (OTC: OTSKF) (OTC: OTSKY) (Otsuka) and H.

Via Benzinga

Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches ↗

November 03, 2022

Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people.

Via Benzinga

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact ↗

July 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Has A Sugar Daddy Emerged In The Psychedelic Drug Industry? ↗

January 31, 2022

One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry.

Via Talk Markets

4 Pre-Merger SPACs to Buy That Are Poised to Soar ↗

November 16, 2021

From quantum computing to energy storage, these four SPACs' merger partners could prove to be quite disruptive over the longer term.

Via InvestorPlace

Topics Electric Vehicles

Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia ↗

June 01, 2021

Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat...

Via Benzinga

3 Cheap Pharmaceutical Stocks to Grab Now ↗

May 28, 2021

The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus.

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.